Pain‐Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies
Pain-related QoL improved with emicizumab prophylaxis regardless of target joints, age, FVIII inhibitor status or prior treatment. Haemophilia-specific assessments are needed to accurately capture and characterize pain in PwHA.
Authors
- Cedric R.J.R. Hermans (ORCID: https://orcid.org/0000-0001-5429-8437)
- Tyler W. Buckner (ORCID: https://orcid.org/0000-0003-1954-4385)
- Miranda Minhas (ORCID: https://orcid.org/0000-0003-2264-3608)
- Elise Lim (ORCID: https://orcid.org/0000-0001-8967-8464)
- Brittany Gentile (ORCID: https://orcid.org/0000-0002-6302-5593)
- Eunice Tzeng
- Mark W. Skinner (ORCID: https://orcid.org/0000-0002-0934-0680)
- Katya Moreno
Institutions
- Roche (Switzerland) (CH)
- Cliniques Universitaires Saint-Luc (BE)
- Statistical Research (United States) (US)
- Impact (CA)
- University of Colorado Denver (US)
- UCLouvain (BE)
- McMaster University (CA)
Publication Details
- Journal
- Haemophilia
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1111/hae.15134
- Citations
- 4
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- F. Hoffmann-La Roche